مباشر
FierceBiotechPulnovo Medical scores $100M in finance round led by MedtronicLonza NewsLonza Group AG stock (CH0013841017): Why biopharma contract manufacturing now matters more for U.S. - AD HOC NEWS10x Genomics BlogIs Atera’s New Spatial Biology Platform Altering The Investment Case For 10x Genomics (TXG)? - simplywall.stBrady CorporationMilwaukee’s Brady Corp Buying Honeywell Division - Seehafer NewsFierceBiotechFoundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic targetFierceBiotechIn a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancerFierceBiotechRay Therapeutics shines a light on $125M round targeting genetic eye therapyFierceBiotechTortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from AsiaFierceBiotechPfizer's strategy head Andrew Baum to step down following brief tenure: reportsBioWorldPricing standoff leaves Australian patients in limboBioWorldMabwell turns to Hong Kong to fund ADC ambitionsBioWorldXuanzhu shares dip despite phase III ALK inhibitor data
eLife ٢٦ يناير ٢٠٢٦

Phenylhydrazone-based endoplasmic reticulum proteostasis regulator compounds with enhanced biological activity

Phenylhydrazone-based endoplasmic reticulum proteostasis regulator compounds with enhanced biological activity

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.